Cardiac Ablation Market Size By Product (Radiofrequency (RF) Ablators, Electrical Ablators, Cryoablation Devices, Ultrasound Ablators), By Approach (Catheter-Based, Open/Surgical), By Application (Atrial Fibrillation & Flutter, Tachycardia), By End-use (Hospitals, Ambulatory Surgical Centers, Cardiac Centers), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028

Industry trends

Cardiac Ablation Market size valued at USD 3.2 billion in 2021 and is expected to grow at a CAGR of over 14.2% between 2022 and 2028. The market growth is attributed to the increasing demand for advanced minimally invasive technologies, especially, in developed countries.

Get more details on this report - Request Free Sample PDF
 

Several benefits associated with minimally invasive procedures such as reduced surgical complications, rapid recovery, shorter stay in the hospitals, and effective management of post-surgical pain are poised to drive the patient preference towards such treatments in coming years, thereby positively impacting the market expansion.
 

As per the Centers for Disease Control and Prevention, nearly 12.1 million people are projected to have AFib in 2030 in the U.S. Population aging further contributes to the disease burden. As aging causes changes in heart structure, elderly population is more prone to cardiovascular diseases. Thus, growing geriatric population across the globe is anticipated to augment the demand for related treatment procedures. Therefore, increasing patient admissions suffering through abnormal cardiac rhythm will positively impact the product demand during the forecast period.
 

Awareness regarding the availability of advanced treatments will stimulate the industry growth

Growing awareness among population regarding the available advanced treatment procedures for cardiac diseases will benefit the market progression. Government is undertaking several initiatives to broaden awareness for better management of cardiac diseases.  For instance, a World Heart Rhythm Week organized by the government is aimed to promote and generate awareness regarding heart rhythm disorders. Further, collaborative efforts by the government and non-government organizations to offer cost-effective treatment to patient will influence the procedural volume. With rising number of ablation procedures, the demand for products will also increase in the coming years.
 

The emergence of COVID-19 has negatively impacted the procedural volume of cardiac ablation to greater extent due to limitations on movement with lockdown in majority of regions across the globe. Further, increased risk of infection at healthcare settings with sudden spike in hospitals admissions has restricted the patients to undergo cardiac procedures. With declining number of cardiovascular procedures, the industry witnessed limited demand for products. However, with declining number of COVID-19 cases over the period, the industry is slated to gain momentum.
 

High reliability and improved mobility associated with radiofrequency (RF) ablation to accelerate product demand

Radiofrequency (RF) ablators segment in the cardiac ablation market is estimated to showcase 14.1% growth rate through 2028 led by the increasing product availability in the market. Several benefits associated with radiofrequency (RF) ablation including cost-effectiveness and quick relief will acceptance the segment growth in the coming years. Additionally, RF ablation provides improved mobility, minimal reliance on painkillers and lasting pain alleviation.
 

Significant increase in cardiac catherization will foster the industry progression

Catheter-based segment held majority of revenue share in 2021 on account of the increasing demand of catheter-based ablation. Higher prevalence of arrhythmias is projected to contribute to the demand for catheter ablation. In addition, minimal recovery time in comparison to open heart surgeries will benefit the segment expansion.
 

Enhanced treatment outcomes with cardiac ablation among atrial fibrillation patients to boost the overall market value

Get more details on this report - Request Free Sample PDF
 

Cardiac ablation market for atrial fibrillation & flutter segment exceeded USD 1.6 billion in 2021. As per the Centers for Disease Control and Prevention, in 2019, atrial fibrillation was mentioned cause of nearly 26,535 deaths in the U.S. Thus, it is considered as a majorly occurring form of cardiac arrhythmia among population and is set to fuel the number of ablation procedures as ablation is commonly performed on patients of atrial fibrillation.
 

Growing rate of disease diagnosis at hospitals will propel the number of treatment procedures

Hospital segment crossed USD 1.8 billion in 2021. Increase in number of patient visits leading to high rate of disease diagnoses carried out in hospital settings will result into increase in number of cardiac ablation procedures. Furthermore, as per the National Health Expenditures report 2019, hospital care expenditure was accounted for nearly 32% of overall healthcare expenditures in the U.S.
 

Presence of leading players in North America providing advanced solutions to offer industry expansion opportunities

Get more details on this report - Request Free Sample PDF

North America cardiac ablation market held more than 40% of revenue share in 2021 impelled by the rising burden of cardiovascular diseases. According to the Centers for Disease Control and Prevention, around 18.2 million adults in the U.S. are predicted to have cardiovascular diseases. Thus, growing number of patient pool is projected to augment the product demand. Additionally, higher adoption of advanced technology, rising healthcare expenditure and presence of leading industry leaders will fuel the regional growth.
 

Key industry participants are focusing on strategic acquisitions and collaborations to strengthen their market footprint

Notable key companies operating in the market are Abbott Laboratories, AngioDynamics, Inc, AtriCure Inc, Biosense Webster (Johnson & Johnson), Biotronik SE & Co. KG, Boston Scientific Corporation, Japan Lifeline, Medtronic plc, MicroPort Scientific Corporation and Stereotaxis, Inc. These market players are undertaking several growth strategies such as collaboration, partnership, merger and acquisitions to gain competitive edge and broaden their industry presence.
 

The cardiac ablation market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Market, By Product

• Radiofrequency (RF) Ablators
• Electrical Ablators
• Cryoablation Devices
• Ultrasound Ablators
• Others

Market, By Approach

• Catheter-based
• Open/Surgical

Market, By Application

• Atrial Fibrillation & Flutter
• Tachycardia
• Others

Market, By End-use

• Hospitals
• Ambulatory surgical centers
• Cardiac centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • France
  • Germany
  • Spain
  • Italy
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE